A5075523186- DNA Repair Mechanisms
- PARP inhibition in cancer therapy
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- BRCA gene mutations in cancer
- Single-cell and spatial transcriptomics
- RNA Interference and Gene Delivery
- Cancer Cells and Metastasis
- Cell death mechanisms and regulation
- Microtubule and mitosis dynamics
- Plant Genetic and Mutation Studies
The University of Queensland
2021
QIMR Berghofer Medical Research Institute
2014-2021
The triple-negative breast cancer (TNBC) subtype represents a that is highly aggressive with poor patient outcome. Current preclinical success has been gained through synthetic lethality, targeting genome instability PARP inhibition in cells harbor silencing of the homologous recombination (HR) pathway. Histone deacetylase inhibitors (HDACi) are class drugs mediate epigenetic changes expression HR pathway genes. Here, we compare activity pan-HDAC inhibitor suberoylanilide hydroxamic acid...
Chemotherapy is used as a standard-of-care against cancers that display high levels of inherent genome instability. induces DNA damage and intensifies pressure on the repair pathways can lead to deregulation. There an urgent clinical need be able track emergence driven chemotherapy resistance tailor patient staging appropriately. have been numerous studies into chemoresistance but date no study has elucidated in detail roles key components associated with frontline combination anthracyclines...
<div>Abstract<p>The triple-negative breast cancer (TNBC) subtype represents a that is highly aggressive with poor patient outcome. Current preclinical success has been gained through synthetic lethality, targeting genome instability PARP inhibition in cells harbor silencing of the homologous recombination (HR) pathway. Histone deacetylase inhibitors (HDACi) are class drugs mediate epigenetic changes expression HR pathway genes. Here, we compare activity pan-HDAC inhibitor...
<div>Abstract<p>The triple-negative breast cancer (TNBC) subtype represents a that is highly aggressive with poor patient outcome. Current preclinical success has been gained through synthetic lethality, targeting genome instability PARP inhibition in cells harbor silencing of the homologous recombination (HR) pathway. Histone deacetylase inhibitors (HDACi) are class drugs mediate epigenetic changes expression HR pathway genes. Here, we compare activity pan-HDAC inhibitor...
Abstract Background: Chemotherapy intensifies pressure on the DNA repair pathways that can lead to deregulation. There is an urgent clinical need be able track emergence of chemotherapy resistance and tailor patient staging appropriately. This especially evident in triple negative breast cancer (TNBC) subtype, which standard care with tumours displaying high levels inherent genome instability. TNBC has overall poor prognosis for survival. have been numerous studies into single agent...